CD274 and cancer: It is not surprising that cancers expressing high levels of antigen‐presenting molecules and chemokines respond better to BCG immunotherapy 101, 102 and the increase of PD‐L1 positivity in cancer cells and TICs after BCG induction has been associated with poor outcome 103, 104, 105, explaining the high BCG treatment recurrence/resistance risk of NMIBC with carcinoma in situ85, which has the high frequency (45%) of PD‐L1 expression 104.